When was Arranta Bio founded?

Arranta Bio was founded in 2019 and raised its 1st funding round within a year of its incorporation.

Where is Arranta Bio located?

Arranta Bio is headquartered in Watertown, United States.

Who is the current CEO of Arranta Bio?

Mark Bamforth of Arranta Bio. They are also angel investors in 4 startups, including Gallus Biopharma.

How many employees does Arranta Bio have?

As of May 31, 2026, the latest employee count at Arranta Bio is 176.

Is Arranta Bio a funded company?

Arranta Bio is a funded company, having raised a total of $***** in its 1st and only funding round, a Series C round on Oct 30, 2019.

When was the latest funding round of Arranta Bio?

Arranta Bio's latest funding was a $***** Series C round on Oct 30, 2019, with participation from 2 investors. Its primary sector is Biopharma Outsourcing. In United States, the Biopharma Outsourcing sector has seen $432M in funding in 2026 to date.

Where does Arranta Bio rank among its competitors?

Arranta Bio ranks 30th amongst 309 active competitors, of which 20 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Abingdon Health, which secured $4.4M in Oct, 2025.

Who are the top competitors of Arranta Bio?

Arranta Bio's top competitors include Anthem Biosciences, Patheon and KBI Biopharma. Among them, Abingdon Health secured the most recent funding round in October, 2025.

Arranta Bio - 2026 Company Profile, Team, Funding & Competitors

Arranta Bio is an acquired company based in Watertown (United States), founded in 2019 by Mark Bamforth. It operates as a Developer of therapeutics for microbiome based diseases. Arranta Bio has raised $82M in funding from Ampersand Capital and Thermo Fisher Scientific. The company has 309 active competitors, including 20 funded and 98 that have exited. Its top competitors include companies like Anthem Biosciences, Patheon and KBI Biopharma.

Company Details

Arrantabio is a contract development and manufacturing organization focusing on the development of therapeutics for the treatment of human microbiome-related diseases. The company develops live biotherapeutic products through bacterial fermentation, isolation, drying, and encapsulation technologies for treating diseases associated with the human microbiome. It offers companies development and cGMP services such as cell banking, frozen blend, drug substance, primary packaging, analytical services and many more.

Website: arrantabio.com
Social
Email ID: *****@arrantabio.com

Key Metrics

Founded Year

2019

Location

Watertown, United States

Stage

Acquired

Total Funding

$82M in 1 round

Latest Funding Round

Series C, Oct 30, 2019, $*****

Investors

Ampersand Capital & 1 more

Ranked

30^th among 309 active competitors

Employee Count

176 as on May 31, 2026

Investment & Acquisitions

Captozyme

Similar Companies

KBI Biopharma & 158 more

Exit Details

Acquired by Recipharm (Feb 27, 2022)

View Arranta Bio's full profile

Arranta Bio got acquired by Recipharm on Feb 27, 2022.

Click here to take a look at Arranta Bio's acquisition in detail

Arranta Bio has raised a total funding of $82M over 1 round. Its latest funding round was a Series C round on Oct 30, 2019 for $*****. 2 investors participated in its latest round. Arranta Bio has 2 institutional investors.

Here is the list of recent funding rounds of Arranta Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 30, 2019	7126594	Series C	4192846	3139048	2756850	7885394

Access funding benchmarks and valuations. Sign up today!

View details of Arranta Bio's funding rounds and investors

The founders of Arranta Bio is Mark Bamforth.

Here are the details of Arranta Bio's key team members:

Mark Bamforth: Founder & CEO of Arranta Bio and founder of 1 other company. They are also an angel investor in 4 startups.

View details of Arranta Bio's Founder profiles and Board Members

Arranta Bio's employee count trend

Arranta Bio has 176 employees as of May 26. Here is Arranta Bio's employee count trend over the years:

Uncover Arranta Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Arranta Bio include Anthem Biosciences, Patheon and KBI Biopharma. Here is the list of Top 10 competitors of Arranta Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Anthem Biosciences 2006, Bengaluru (India), Public	Developer of integrated contract research development and manufacturing services	$35.7M	Portsmouthtechnologiestrialsunit, True North ... & 8 others	77/100
2nd	Patheon 1974, Durham (United States), Acquired	Global CDMO providing integrated drug development, clinical trials, and manufacturing services	$141M	JLL Partners, Frazier Healthcare Partners ... & 3 others	75/100
3rd	KBI Biopharma 1996, Durham (United States), Acquired	Provider of protein formulation, process & cell line development, and cGMP services	$21M	NCBiotech, Vencore Capital & 1 others	68/100
4th	Syngene 1993, Bengaluru (India), Public	Provider of contract research and manufacturing services for both small molecules and biologics	$85.9M	True North, ADIA & 9 others	66/100
5th	Abzena 2001, Cambridge (United Kingdom), Acquired	Provider of antibody discovery, cell line development, and bio analytics services	$67.1M	Imperial Innovations, Mercia & 11 others	66/100
6th	Abingdon Health 2008, York (United Kingdom), Public	Developer of immunoassays for diagnostic purposes	$24.1M	Imperial Innovations, Mercia & 2 others	64/100
7th	Panacea Biotec 1984, Ambala (India), Public	Developer of biosimilars, vaccines and natural products	-	India Resurgence Fund, Department of Biotechnology ... & 1 others	62/100
8th	Grand River Aseptic Manufacturing 2010, Grand Rapids (United States), Acquired	Aseptic manufacturing CDMO providing fill-finish services for sterile injectables	$16.9M	Municipal Employees' Retirement System, Charter Capital Partners ... & 5 others	59/100
9th	EirGenix 2012, Taipei (Taiwan), Public	Contract development and manufacturing organization for biologics	-	CDIB Capital Group, Taiwania Capital & 3 others	58/100
10th	OBiO Technology 2013, Shanghai (China), Public	Provider of viral based gene therapy CRO services	$87.1M	Loayal Valley Capital, Efung Capital & 11 others	58/100
30th	Arranta Bio 2019, Watertown (United States), Acquired	Developer of therapeutics for microbiome based diseases	$82M	Ampersand Capital, Thermo Fisher Scientific	48/100